ClinicalTrials.gg
CompletedNCT00889226ESPRITUpdated Sep 17, 2019Results posted

Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia

A Phase 4 interventional study of Pitavastatin and Atorvastatin in Hypercholesterolemia With Type2DM, sponsored by JW Pharmaceutical. Completed. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-17.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
14th of 19
161 · median 200
Started
2008
with 2 others
Phase 4
8 of 19
none open now
Registered
14th of 19
by date
Lead sponsor
4 of 19
JW Pharmaceutical

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 14th largest by enrollment, is one of 3 that started in 2008, is one of 8 in phase 4, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia

Read the detailed description

To evaluate the effect of pitavastatin compared to atorvastatin on the change of Lipid profiles, ApoA1, ApoB, adiponectin and baPWV as a marker of atherosclerosis in Type 2DM .

03

Conditions studied

  • Hypercholesterolemia With Type2DM

Keywords

  • pitavastatin
  • PWV
  • ESPRIT
  • Pitavastatin and Atorvastatin
  • Adiponectin
  • fasting insulin
  • hs-CRP
  • baPWV
04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 25yrs\~75yrs
  • Fasting TG \<400mg/dL, LDL-C ≥130mg/dL
  • 3months > Diagnosed Type2 DM, With OAD, ≤ 10.0% or First Diagnosed Type2 DM, 6.5%≤HbA1c≤10.0%

Exclusion criteria

Exclusion Criteria:

  • Type1 DM, Gestational diabetes
  • Patient need to treat with Insulin
  • Patient with operational treatment for severe diabetic complication
  • Uncontrolled Hypothyroidism
  • Unstable angina, MI, (TIA), Stroke, PCI, Heart Failure within 3 months ( class4)
  • Severe Hypertension (SBP ≥ 180 or DBP ≥ 110mmHg)
  • Renal disorder (Serum creatinine ≥ 2.0mg/dL)
  • Hepatic disorder ( or ALT ≥ 2.5 X UNL)
  • Creatinine Kinase > 2.5 X UNL
  • Gravida or lactation phase
  • Administration of Atorvastatin, Rosuvastatin, Pitavastatin
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Pitavastatin Group

    Drug: Pitavastatin

  • Active comparator
    Atorvastatin Group

    Drug: Atorvastatin

Interventions

  • Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks

    Also known as: Livalo

  • Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks

    Also known as: Lipitor

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Achieving LDL- C<100mg/dL

    compare the proportion of patients achieving LDL- C\<100mg/dL

    Time frame: After 16wk drug administration

Secondary outcomes

  1. The Change of LDL-C

    The change of LDL-C between at 16-week and baseline

    Time frame: After 16wk drug administration

07

Results

Posted Sep 17, 2019

Participant flow

Participant flow — Overall Study
MilestonePitavastatin GroupAtorvastatin Group
Started8378
Completed5843
Not completed2535

Outcome measures

PrimaryProportion of Patients Achieving LDL- C<100mg/dL

compare the proportion of patients achieving LDL- C\<100mg/dL

Time frame:
After 16wk drug administration
Reported as:
Count of participants · Participants
Proportion of Patients Achieving LDL- C<100mg/dL
ParticipantsPitavastatin GroupAtorvastatin Group
Proportion of Patients Achieving LDL- C<100mg/dL6154
SecondaryThe Change of LDL-C

The change of LDL-C between at 16-week and baseline

Time frame:
After 16wk drug administration
Reported as:
Mean · mg/dl
The Change of LDL-C
mg/dlPitavastatin GroupAtorvastatin Group
The Change of LDL-C-69.8 ± 22.5-70.9 ± 28.2

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin Group0/81 (0%)0/81 (0%)3/81 (3.7%)
Atorvastatin Group0/70 (0%)0/70 (0%)0/70 (0%)
Most frequent other events
Most frequent other events
EventPitavastatin GroupAtorvastatin Group
coughingRespiratory, thoracic and mediastinal disorders3/810/70

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pitavastatin GroupAtorvastatin GroupTotal
Mean59.6 (35.0 to 74.0)59.1 (41.0 to 74.0)59.3 (35 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin GroupAtorvastatin GroupTotal
Female5554109
Male282452
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Pitavastatin GroupAtorvastatin GroupTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Pitavastatin GroupAtorvastatin GroupTotal
South Korea8378161
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of May 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 10 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2009
First posted
Apr 28, 2009
Start
Apr 2008
Primary completionActual
May 2009
CompletionActual
Jan 2010
Results first posted
Sep 17, 2019
Last update
Sep 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00889226
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Apr 28, 2009
Start date
Apr 2008
Primary completion
May 2009
Completion
Jan 2010
Results posted
Sep 17, 2019
Last update
Sep 17, 2019

Study contacts

Ho Young Shon, MD
principal investigator · Endocrinology, Kangnam Saint Mary's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion